Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
59,746,870
-
Total 13F shares
-
48,320,278
-
Share change
-
+3,855,511
-
Total reported value
-
$1,129,227,408
-
Put/Call ratio
-
4.9%
-
Price per share
-
$23.37
-
Number of holders
-
92
-
Value change
-
+$91,685,963
-
Number of buys
-
66
-
Number of sells
-
25
Institutional Holders of Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN) as of Q2 2024
As of 30 Jun 2024 Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN) had 92 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 48,320,278 shares of stock of the company.
Largest 10 holders included ORBIMED ADVISORS LLC, FMR LLC, VR Adviser, LLC, COMMODORE CAPITAL LP, Fairmount Funds Management LLC, BlackRock Inc., 5AM Venture Management, LLC, CITADEL ADVISORS LLC, RA CAPITAL MANAGEMENT, L.P., and VANGUARD GROUP INC.
This table shows 91 institutional shareholders of the security as of 30 Jun 2024.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.